The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy
Open accessAbstract
BACKGROUND: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the alpha chain and a noncovalently associated, soluble protein called beta2-microglobulin (beta 2m). Loss of beta 2m generally eliminates antigen recognition by antitumor CD8+ T cells. PURPOSE: We studied the loss of beta 2m as a potential means of tumor escape from immune recognition in a cohort of patients receiving immunotherapy. METHODS: We successfully grew 13 independent tumor cell cultures from tumor specimens obtained from 13 patients in a cohort of 40 consecutive patients undergoing immunotherapy for metastatic melanoma and for whom tumor specimens were available. These cell lines, as well as another melanoma cell line (called 1074mel) that had been derived from tumor obtained from a patient in a cytokine-gene therapy study, were characterized in vitro cytofluorometrically for MHC class I expression and by northern and western blot analyses for messenger RNA (mRNA) and protein expression, respectively, and ex vivo by immunohistochemistry. RESULTS: After one melanoma cell line (1074mel) was found not to express functional beta 2m by cytofluorometric analysis, four (31%) of the 13 newly established melanoma cell lines were found to have an absolute lack of functional MHC class I expression. Northern blot analysis of RNA extracted from the five cell lines exhibiting no functional MHC class I expression showed that these cells contained normal levels of alpha-chain mRNA but variable levels of beta 2m mRNA. In addition, no immunoreactive beta 2m protein was detected by western blot analysis. When human beta 2m was transiently expressed with the use of a recombinant vaccinia virus, cell-surface MHC class I expression was reconstituted and the ability of these five cell lines to present endogenous antigens was restored. Immunohistochemical staining of tumor sections revealed a lack of immunoreactive MHC class I in vivo, supporting the notion that the in vitro observations were not artifactual. Furthermore, archival tumor sections obtained from patients prior to immunotherapy were available from three patients and were found to be beta 2m positive. This result was consistent with the hypothesis that loss of beta 2m resulted from immunotherapy. CONCLUSIONS: These data suggest that the loss of beta 2m may be a mechanism whereby tumor cells can acquire immunoresistance. This study represents the first characterization of a molecular route of escape of tumors from immune recognition in a cohort of patients being treated with immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the human class I histocompatibility antigen, HLA-A2
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329506a0 · Cited by 3,472
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., & Wiley, D. C. (1993) · Nature · doi:10.1038/364033a0 · Cited by 2,379
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329512a0 · Cited by 2,377
Rosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,019
Self-citationβ2-Microglobulin deficient mice lack CD4−8+ cytolytic T cells
Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., & Jaenisch, R. (1990) · Nature · doi:10.1038/344742a0 · Cited by 1,012
Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., & Rosenberg, S. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.347 · Cited by 862
Self-citationCrystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2K b
Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., & Wilson, L. A. (1992) · Science · doi:10.1126/science.1323877 · Cited by 861
Emerging Principles for the Recognition of Peptide Antigens by MHC Class I Molecules
Matsumura, M., Fremont, D. H., Peterson, P. A., & Wilson, L. A. (1992) · Science · doi:10.1126/science.1323878 · Cited by 731
Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice
Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., & Ochoa, A. C. (1992) · Science · doi:10.1126/science.1465616 · Cited by 632
Identification of human cancers deficient in antigen processing.
Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mulé, J. J., Rosenberg, S. A., & Bennink, J. R. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.2.265 · Cited by 624
Self-citationFisk, B., Blevins, T. L., Wharton, J. T., & Ioannides, C. G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.6.2109 · Cited by 543
HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation
Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546329 · Cited by 520
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
Topalian, S. L., Solomon, D., & Rosenberg, S. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.10.3714 · Cited by 512
Self-citationInduction of MHC Class I Genes in Neurons
Neumann, H., Cavalié, A., Jenne, D. E., & Wekerle, H. (1995) · Science · doi:10.1126/science.7624779 · Cited by 449
Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., & Eberlein, T. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.432 · Cited by 439
Eichelberger, M., Allan, W., Zijlstra, M., Jaenisch, R., & Doherty, P. C. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.875 · Cited by 366
Zijlstra, M., Li, E., Sajjadi, F., Subramani, S., & Jaenisch, R. (1989) · Nature · doi:10.1038/342435a0 · Cited by 347
Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., & Walboomers, J. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.1.335 · Cited by 330
Townsend, A., Bastin, J., Gould, K., Brownlee, G., Andrew, M., Coupar, B., Boyle, D., Chan, S., & Smith, G. (1988) · The Journal of experimental medicine · doi:10.1084/jem.168.4.1211 · Cited by 327
Peptide Specificity in the Recognition of MHC Class I by Natural Killer Cell Clones
Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, E., Moretta, A., & Long, E. O. (1995) · Science · doi:10.1126/science.7863326 · Cited by 309
D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci114984 · Cited by 309
Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells
Hou, S., Doherty, P. C., Zijlstra, M., Jaenisch, R., & Katz, J. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.4.1319 · Cited by 234
Hoppe, R. T., Medeiros, L. J., Warnke, R. A., & Wood, G. S. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90067-5 · Cited by 182
MHC molecules as peptide receptors
Rammensee, H.-G., Falk, K., & Rötzschke, O. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90078-7 · Cited by 168
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., Mixon, A., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.3.1225 · Cited by 165
Self-citationRestifo, N. P., Spiess, P. J., Karp, S. E., Mulé, J. J., & Rosenberg, S. A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.6.1423 · Cited by 161
Self-citationBeta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.
Bicknell, D. C., Rowan, A., & Bodmer, W. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4751 · Cited by 150
Peoples, G. E., Blotnick, S., Takahashi, K., Freeman, M. R., Klagsbrun, M., & Eberlein, T. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6547 · Cited by 141
Esquivel-Guadarrama, F. R., Yewdell, J. W., & Bennink, J. R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.163 · Cited by 137
Molecular Mechanisms Used by Tumors to Escape Immune Recognition
Restifo, N. P., Kawakami, Y., Marincola, F. M., Shamamian, P. E., Taggarse, A., Esquivel-Guadarrama, F. R., & Rosenberg, S. A. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199310000-00004 · Cited by 119
Self-citationRestifo, N. P., Esquivel-Guadarrama, F. R., Asher, A. L., Stötter, H., Barth, R. J., Bennink, J. R., Mulé, J. J., Yewdell, J. W., & Rosenberg, S. A. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1453 · Cited by 113
Self-citationTumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms
Bodmer, W. F., Browning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., & Bodmer, J. G. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb43994.x · Cited by 107
Prevention of insulitis and diabetes in Β2-microglobulin-deficjent non-obese diabetic mice
Sumida, T., Furukawa, M., Sakamoto, A., Namekawa, T., Maeda, T., Zijistra, M., Iwamoto, I., Kolke, T., Yoshida, S., Tomioka, H., et al. (1994) · International Immunology · doi:10.1093/intimm/6.9.1445 · Cited by 98
Sugita, M., & Brenner, M. B. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.6.2163 · Cited by 94
Wang, Z., Cao, Y., Albino, A. P., Zeff, R. A., Houghton, A., & Ferrone, S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116249 · Cited by 91
Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells
Hammond, S. A., Bollinger, R. C., Tobery, T. W., & Siliciano, R. F. (1993) · Nature · doi:10.1038/364158a0 · Cited by 88
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Qin, H., Chen, W., Takahashi, M., Disis, M. L., Byrd, D. R., McCahill, L., Bertram, K. A., Fenton, R. G., Peace, D. J., & Cheever, M. A. (1995) · PubMed · Cited by 65
Maio, M., Altomonte, M., Tatake, R. J., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115289 · Cited by 63
Immune surveillance in colorectal carcinoma
Branch, P., Bicknell, D., Rowan, A., Bodmer, W. F., & Karran, P. (1995) · Nature Genetics · doi:10.1038/ng0395-231 · Cited by 60
Schoof, D. D., Terashima, Y., Peoples, G. E., et al. (1993) · Cellular Immunology · doi:10.1006/cimm.1993.1183 · Cited by 56
Ikarashi, H., Fujita, K., 高桑好一, Kodama, S., Tokunaga, A., Takahashi, T., & Tanaka, K. (1994) · PubMed · Cited by 42
O’Neil, B. H., Kawakami, Y., Restifo, N. P., Bennink, J. R., Yewdell, J. W., & Rosenberg, S. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1410 · Cited by 35
Self-citationCrystallization of murine major histocompatibility complex class I H-2Kb with single peptides
Stura, E. A., Matsumura, M., Fremont, D. H., Saito, Y., Peterson, P. A., & Wilson, L. A. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90881-j · Cited by 33
Cole, D. J., Taubenberger, J. K., Pockaj, B. A., Yannelli, J. R., Carter, C. S., Carrasquillo, J. A., Leitman, S. F., Steinberg, S. M., Rosenberg, S. A., & Yang, Y. (1994) · Cancer Immunology Immunotherapy · doi:10.1007/bf01525507 · Cited by 32
Self-citationZügel, U., Schoel, B., & Kaufmann, S. H. E. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.9.4070 · Cited by 23
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“It was already well documented by the 1990s that some patients who initially respond to cancer immunotherapies with IL-2 or TIL ACT might develop acquired resistance through loss of the shared component of all HLA class I molecules, B2M, which leads to absence of surface expression of HLA class I (D’Urso et al., 1991;…”
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Metadata
- Authors
- Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-01-17
- Volume
- 88
- Issue
- 2
- Pages
- 100-108
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2135808990
- Cited by
- 533
- References
- 45
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.